Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

Press Release   Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)

Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

Paris - June 19, 2018 - Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO) and Member of the Executive Committee, effective October 1^st 2018.  He will join Sanofi September 1^st to ensure a smooth transition with Jérôme Contamine who will retire on September 30^th, after more than 9 years of distinguished service at Sanofi.

Mr. Chasseloup de Chatillon most recently served as Chief Financial Officer and Executive Vice-President for PSA Group. In this capacity he was also a member of the Managing Board and of the Executive Committee. Throughout his tenure at PSA Group, he held various management positions in finance (Treasurer in Spain, Chief Financial Officer in the United Kingdom) and in sales and marketing (Citroen Belgium Managing Director.) He was also Chairman of the Board of Banque PSA Finance (BPF) from 2012 to June 2016. He has been a member of the Peugeot S.A. Managing Board since 2012.

"Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group. His track record of successfully driving finance across different businesses and geographies throughout his career will be of great value to lead our very experienced team around the world," says Olivier Brandicourt, Chief Executive Officer at Sanofi. "I would like to express my thanks and gratitude to Jerome Contamine for his excellent service to Sanofi during the company's transformation over the past decade. He has been a highly committed and trusted business partner to me and to my executive team."

A citizen of France, Mr. Chasseloup de Chatillon holds a Master from Paris Dauphine and studied Finance in the UK (Lancaster University).

About Sanofi   Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.   With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.   Sanofi, Empowering Life

Media Relations Contact Laurence Bollack Tél.: [phone] [e-mail]

Investor Relations Contact George Grofik Tel.: [phone] [e-mail]

Press release (PDF)

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire